Clinical Trial Update: VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating VR-CAP as first-line therapy for Marginal Zone Lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PREDNISONE (Prednisone)
• Rituximab (rituximab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: COMPLETED